maddox_et_al_2024_2024_acc_expert_consensus_decision_pathway_for.pdf
5.7 MB
2024 ACC HFrEF experts Guideline
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
American College of Cardiology
https://www.tgoop.com/PIC_uptodate77
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
American College of Cardiology
https://www.tgoop.com/PIC_uptodate77
Forwarded from اللجنة العلمية# الدفعة الرابعة ❈صيدلة❈ (رانيا عامر)
The International Society for the Study of Hypertension in Pregnancy (ISSHP) classification of pre-eclampsia.
pack_et_al_2024_teratogenesis_perinatal_and_neurodevelopmental_outcomes.pdf
413.4 KB
2024 New Guidelines; Epilepsy and Pregnancy
American Academy of Neurology
https://www.tgoop.com/PIC_uptodate77
American Academy of Neurology
https://www.tgoop.com/PIC_uptodate77
GOLD-2024_v1.2-11Jan24_WMV.pdf
15.1 MB
الجديد في الCOPD
2024 Global Strategy for The Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
https://www.tgoop.com/PIC_uptodate77
2024 Global Strategy for The Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
https://www.tgoop.com/PIC_uptodate77
gornik_et_al_2024_2024_acc_aha_aacvpr_apma_abc_scai_svm_svn_svs.pdf
3.9 MB
الجديد
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease:
A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
https://www.tgoop.com/PIC_uptodate77
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease:
A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
https://www.tgoop.com/PIC_uptodate77
Pharmacotherapy Information Center ( PIC )
Photo
DEFENCATH
دواء جديد تم إضافته مع الهيبارين ليكون
صنف دوائي جديد يحتوي على combination من الHeparin and taurolidine
حيث أن الtaurolidine دواء مضاد للميكروبات Antimicrobial drug
هذا المركب الدوائي تحت اسم DEFENCATH
Initial U.S. Approval: 2023
هذا المركب الدوائي(DEFENCATH ) يستخدم لتقليل حدوث العدوى المصاحبة للقسطرة (CRBSI) عند مرضى الفشل الكلوي البالغين الذين يخضعون لغسيل كلوي مزمن بواسطة Central Venous Catheter (CVC)
💊DEFENCATH (taurolidine and heparin) catheter lock solution, for central venous catheter instillation use
1⃣INDICATIONS AND USAGE
DEFENCATH is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
2⃣Limitations of Use
The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
3⃣-DOSAGE AND ADMINISTRATION
DEFENCATH is for instillation into CVCs only.
DEFENCATH is not intended for systemic administration.
Do not use DEFENCATH as a catheter lock flush product.
Withdraw a sufficient volume of DEFENCATH catheter lock solution (CLS) from the vial using a sterile needle and syringe to fill the catheter lumens.
Use 3 mL or 5 ml. single dose vial (depending on the volume of the catheter lumens) to instill DEFENCATH into each catheter lumen at the conclusion of each HD session.
DEFENCATH must be aspirated from the catheter and discarded prior to the initiation of the next HD session.
Discard any unused portion of DEFENCATH remaining in the vial.
4⃣DOSAGE FORMS AND STRENGTHS--
DEFENCATH is a sterile catheter lock solution available in single-
dose vials in the following strengths:
3 mL containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL)
5 mL containing taurolidine 67.5 mg/5 mL (13.5 mg/mL), and heparin 5,000 USP Units/5 mL (1,000 USP Units/mL)
5⃣---CONTRAINDICATIONS-
Known heparin-induced thrombocytopenia.
Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products.
6⃣---WARNINGS AND PRECAUTIONS---
Heparin-Induced Thrombocytopenia (HIT): HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures.
Drug Hypersensitivity Reactions: Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% in patients using heparin, a component of DEFENCATH, as a CLS. If a hypersensitivity reaction occurs, discontinue DEFENCATH and institute appropriate supportive measures.
7⃣ADVERSE REACTIONS--
The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients in Trial 1 using DEFENCATH as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
https://www.tgoop.com/PIC_uptodate77
دواء جديد تم إضافته مع الهيبارين ليكون
صنف دوائي جديد يحتوي على combination من الHeparin and taurolidine
حيث أن الtaurolidine دواء مضاد للميكروبات Antimicrobial drug
هذا المركب الدوائي تحت اسم DEFENCATH
Initial U.S. Approval: 2023
هذا المركب الدوائي(DEFENCATH ) يستخدم لتقليل حدوث العدوى المصاحبة للقسطرة (CRBSI) عند مرضى الفشل الكلوي البالغين الذين يخضعون لغسيل كلوي مزمن بواسطة Central Venous Catheter (CVC)
💊DEFENCATH (taurolidine and heparin) catheter lock solution, for central venous catheter instillation use
1⃣INDICATIONS AND USAGE
DEFENCATH is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
2⃣Limitations of Use
The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
3⃣-DOSAGE AND ADMINISTRATION
DEFENCATH is for instillation into CVCs only.
DEFENCATH is not intended for systemic administration.
Do not use DEFENCATH as a catheter lock flush product.
Withdraw a sufficient volume of DEFENCATH catheter lock solution (CLS) from the vial using a sterile needle and syringe to fill the catheter lumens.
Use 3 mL or 5 ml. single dose vial (depending on the volume of the catheter lumens) to instill DEFENCATH into each catheter lumen at the conclusion of each HD session.
DEFENCATH must be aspirated from the catheter and discarded prior to the initiation of the next HD session.
Discard any unused portion of DEFENCATH remaining in the vial.
4⃣DOSAGE FORMS AND STRENGTHS--
DEFENCATH is a sterile catheter lock solution available in single-
dose vials in the following strengths:
3 mL containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL)
5 mL containing taurolidine 67.5 mg/5 mL (13.5 mg/mL), and heparin 5,000 USP Units/5 mL (1,000 USP Units/mL)
5⃣---CONTRAINDICATIONS-
Known heparin-induced thrombocytopenia.
Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products.
6⃣---WARNINGS AND PRECAUTIONS---
Heparin-Induced Thrombocytopenia (HIT): HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures.
Drug Hypersensitivity Reactions: Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% in patients using heparin, a component of DEFENCATH, as a CLS. If a hypersensitivity reaction occurs, discontinue DEFENCATH and institute appropriate supportive measures.
7⃣ADVERSE REACTIONS--
The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients in Trial 1 using DEFENCATH as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
https://www.tgoop.com/PIC_uptodate77
Telegram
Pharmacotherapy Information Center ( PIC )
مصدر معلومات لكل مهتم بالطب بشكل عام والمعالجة الدوائية (Pharmacotherapy) وكل ماهو حديث في هذا المجال
MAbs.pptx
1.5 MB
Monoclonal Antibodies;
أ.د.غمدان الطاهش
مناعة سريرية
كلية الصيدلة السريرية
جامعة ٢١سبتمبر
https://www.tgoop.com/PIC_uptodate77
أ.د.غمدان الطاهش
مناعة سريرية
كلية الصيدلة السريرية
جامعة ٢١سبتمبر
https://www.tgoop.com/PIC_uptodate77
Mediterranean_Diet_Toolkit_A_Guide_to_Healthy_Eating_handout.pdf
1.2 MB
🥗Mediterranean Diet
حمية البحر الأبيض المتوسط
أفضل نظام غذائي يمكن اتباعه لصحة جيدة والوقاية من الأمراض المزمنة
📌Dietitians of Canada
📌The Global Resource for Nutrition Practice
https://www.tgoop.com/PIC_uptodate77
حمية البحر الأبيض المتوسط
أفضل نظام غذائي يمكن اتباعه لصحة جيدة والوقاية من الأمراض المزمنة
📌Dietitians of Canada
📌The Global Resource for Nutrition Practice
https://www.tgoop.com/PIC_uptodate77
tewari_et_al_2024_drug_induced_acute_dystonia_after_sacubitril_valsartan.pdf
292.1 KB
Drug-induced Acute Dystonia After Sacubitril/Valsartan Combination
⚫️Clinical Cases
📌American College of Physicians (ACP)
📌American Heart Association (AHA)
https://www.tgoop.com/PIC_uptodate77
⚫️Clinical Cases
📌American College of Physicians (ACP)
📌American Heart Association (AHA)
https://www.tgoop.com/PIC_uptodate77
Cholesterol-guide-for-HC-Practitioners-English.pdf
940.3 KB
📋Cholesterol Management Guide for Health Care Practitioner
📌American Heart Association (AHA)
https://www.tgoop.com/PIC_uptodate77
📌American Heart Association (AHA)
https://www.tgoop.com/PIC_uptodate77
PIIS1530891X22000908.pdf
4.9 MB
📋Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
📌American Association of Clinical Endocrinology (AACE)
https://www.tgoop.com/PIC_uptodate77
📌American Association of Clinical Endocrinology (AACE)
https://www.tgoop.com/PIC_uptodate77
Management Algorithm for Nonalcoholic Fatty Liver Disease Overview
📌American Association of Clinical Endocrinology (AACE)
https://www.tgoop.com/PIC_uptodate77
📌American Association of Clinical Endocrinology (AACE)
https://www.tgoop.com/PIC_uptodate77
ضاءت بك الدنيا وعشت ممجدًا..
وغبت عن الدنيا وما زلت سيِّدًا
.. عليك سلام الله في كل خفقة..
فقد ماتت الأسماء إلا محمدًا
في ذكرى المولد النبوي الشريف على صاحبه أفضل الصلاة والسلام ،
أكثرو من الصلاة والسلام على اشرف الانبياء والمرسلين
وغبت عن الدنيا وما زلت سيِّدًا
.. عليك سلام الله في كل خفقة..
فقد ماتت الأسماء إلا محمدًا
في ذكرى المولد النبوي الشريف على صاحبه أفضل الصلاة والسلام ،
أكثرو من الصلاة والسلام على اشرف الانبياء والمرسلين
وُلِـدَ الـهُـدى فَـالكائِناتُ ضِياءُ.. وَفَـمُ الـزَمـانِ تَـبَـسُّـمٌ وَثَناءُ
الـروحُ وَالـمَـلَأُ الـمَلائِكُ حَولَهُ.. لِـلـديـنِ وَالـدُنـيـا بِهِ بُشَراءُ
وَالـعَـرشُ يَزهو وَالحَظيرَةُ تَزدَهي.. وَالـمُـنـتَـهى وَالسِدرَةُ العَصماءُ
وَحَـديـقَـةُ الفُرقانِ ضاحِكَةُ الرُبا.. بِـالـتُـرجُـمـ انِ شَـذِيَّةٌ غَنّاءُ
وَالـوَحيُ يَقطُرُ سَلسَلًا مِن سَلسَلٍ.. وَالـلَـوحُ وَالـقَـلَـمُ البَديعُ رُواءُ
نُـظِمَت أَسامي الرُسلِ فَهيَ صَحيفَةٌ.. فـي الـلَـوحِ وَاِسمُ مُحَمَّدٍ طُغَراءُ
اِسـمُ الـجَـلالَةِ في بَديعِ حُروفِهِ.. أَلِـفٌ هُـنـالِـكَ وَاِسمُ طَهَ الباءُ
#اللهم صل وسلم وبارك وتحنن وترحم على سيدنا محمد وعلى آله وصحبه أجمعين
الـروحُ وَالـمَـلَأُ الـمَلائِكُ حَولَهُ.. لِـلـديـنِ وَالـدُنـيـا بِهِ بُشَراءُ
وَالـعَـرشُ يَزهو وَالحَظيرَةُ تَزدَهي.. وَالـمُـنـتَـهى وَالسِدرَةُ العَصماءُ
وَحَـديـقَـةُ الفُرقانِ ضاحِكَةُ الرُبا.. بِـالـتُـرجُـمـ انِ شَـذِيَّةٌ غَنّاءُ
وَالـوَحيُ يَقطُرُ سَلسَلًا مِن سَلسَلٍ.. وَالـلَـوحُ وَالـقَـلَـمُ البَديعُ رُواءُ
نُـظِمَت أَسامي الرُسلِ فَهيَ صَحيفَةٌ.. فـي الـلَـوحِ وَاِسمُ مُحَمَّدٍ طُغَراءُ
اِسـمُ الـجَـلالَةِ في بَديعِ حُروفِهِ.. أَلِـفٌ هُـنـالِـكَ وَاِسمُ طَهَ الباءُ
#اللهم صل وسلم وبارك وتحنن وترحم على سيدنا محمد وعلى آله وصحبه أجمعين
اللهم صل وسلم وبارك على سيدنا ونبينا محمد